Antioxidant Activity of Telmisartan–Cu(II) Nanoparticles Connected 2-Pyrimidinamine and Their Evaluation of Cytotoxicity Activities

Table 6

Cytotoxic activities of pyrimidinamine derivatives 1a-c, Cu-N, and Cu-N-Pyr.

Compounds	HepG2			MCF-7			HeLa
	GI50 (μM)	TGI (μM)	LC50 (μM)	GI50 (μM)	TGI (μM)	LC50 (μM)	GI50 (μM)	TGI (μM)	LC50 (μM)
1a	03.2	09.3	32.1	0.06	0.62	12.0	0.69	12.3	25.6
1b	02.1	06.1	24.1	12.2	24.3	42.2	0.09	20.3	41.2
1c	06.3	14.3	44.1	10.2	20.3	41.3	12.3	24.6	46.2
Cu-Nps	12.3	24.2	45.3	18.5	36.2	69.6	21.0	46.3	84.0
Cu-Nps-Pyr-1a	0.02	0.21	0.59	0.04	0.28	0.81	0.01	0.19	0.42
Cu-Nps-Pyr-1b	0.01	06.1	24.1	12.2	24.3	42.2	0.12	0.33	0.92
Cu-Nps-Pyr-1c	0.05	14.3	44.1	0.02	0.13	0.53	0.05	0.16	0.36
Doxorubicin	0.01	0.13	0.58	0.02	0.21	0.74	0.05	0.41	0.88